Valuation: Thor Medical

Market Cap 1.75B 183M 165M 153M 138M 261M 17.2B 268M 1.83B 730M 9.21B 688M 674M 29.32B P/E 2026 *
-19.3x
P/E 2027 * -75.4x
Enterprise Value 1.75B 183M 165M 152M 138M 260M 17.15B 267M 1.83B 727M 9.19B 686M 672M 29.24B EV / Sales 2026 *
91.9x
EV / Sales 2027 * 11.9x
Free-Float
75.21%
Yield 2026 *
-
Yield 2027 * -
1 day-1.33%
1 week+2.00%
Current month+1.87%
1 month-7.67%
3 months-35.59%
6 months-8.60%
Current year-22.10%
1 week 3.7
Extreme 3.7
4.21
1 month 3.7
Extreme 3.7
4.52
Current year 3.7
Extreme 3.7
7.12
1 year 3.48
Extreme 3.485
7.12
3 years 0.85
Extreme 0.85
7.12
5 years 0.85
Extreme 0.85
7.12
10 years 0.85
Extreme 0.85
7.12
Manager TitleAgeSince
Chief Executive Officer 41 01/08/2024
Director of Finance/CFO 37 01/07/2023
Chief Tech/Sci/R&D Officer - 01/06/2023
Director TitleAgeSince
Director/Board Member 67 28/06/2023
Chairman 59 -
Director/Board Member - 24/04/2025
Date Insider Type Main position Quantity % Market Cap. Importance
6/26/25 A
Scatec Innovation AS
OthersCompany 31,577,399 10.0434%
6/18/25 A
Scatec Innovation AS
BuyCompany 3,000,000 0.9542%
5/2/25 A Exercice

Director

164,641 0.0524%
Change 5-day change 1-year change 3-year change Capi.($)
-1.33%+2.00%+10.54%+228.25% 183M
+1.10%+1.03%+62.53%+70.47% 67.53B
+0.32%+7.68%+12.88%+90.87% 60.74B
-0.21%-1.25%+19.73%+97.85% 55.66B
+0.09%+8.69%+11.51%+111.68% 47.97B
-1.63%+1.81%+22.09%+39.25% 45.24B
-0.99%+1.28%+173.31%+815.62% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-1.98%-3.08%+79.24%+56.02% 33.45B
-1.91%+9.39%-38.80%+397.78% 26.49B
Average -0.44%+2.12%+37.88%+195.88% 41B
Weighted average by Cap. -0.16%+2.62%+41.21%+167.58%

Financials

2026 *2027 *
Net sales 19M 1.99M 1.79M 1.66M 1.5M 2.83M 187M 2.9M 19.86M 7.92M 99.96M 7.47M 7.31M 318M 143M 15M 13.52M 12.49M 11.29M 21.37M 1.41B 21.9M 150M 59.68M 754M 56.31M 55.11M 2.4B
Net income -80.5M -8.43M -7.6M -7.02M -6.35M -12.01M -791M -12.3M -84.14M -33.54M -424M -31.64M -30.97M -1.35B -23.5M -2.46M -2.22M -2.05M -1.85M -3.51M -231M -3.59M -24.56M -9.79M -124M -9.24M -9.04M -393M
Net Debt -5M -524K -472K -436K -394K -746K -49.12M -764K -5.23M -2.08M -26.31M -1.97M -1.92M -83.71M -43.5M -4.56M -4.11M -3.79M -3.43M -6.49M -427M -6.65M -45.47M -18.12M -229M -17.1M -16.74M -728M
Projected Income Statement - Annual - Thor Medical
Logo Thor Medical
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
Employees
24
Date Price Change Volume
12/11/26 NOK 4.090 -1.33% 435,634
11/11/26 NOK 4.145 -0.60% 1,140,797
10/11/26 NOK 4.170 +1.96% 1,422,485
09/11/26 NOK 4.090 -0.61% 1,058,726
06/11/26 NOK 4.115 +2.62% 2,370,142
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.145NOK
Average target price
5.600NOK
Spread / Average Target
+35.10%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Thor Medical
  1. Stock Market
  2. Stocks
  3. NANOV Stock